FREDERICK, Md., June 2 /PRNewswire-FirstCall/ -- BioElectronics Corporation (OTC Pink Sheets: BIEL), the manufacturer of ActiPatch Therapy, electronic healing patches, has established Middle East distribution. "ActiPatch Therapy is the ideal wound and first aid product to reduce pain, swelling and accelerate healing from surgical and accidental wounds, sprains and strains and other soft tissue injuries," said Andrew J. Whelan, President, BioElectronics Corporation.
The Distribution Agreement with New Horizon Investment and Development, a 12-year-old leading Egyptian distributor of medical devices for Siemens, Select Surgical, and others covers Egypt, Saudi Arabia, Kuwait, Yemen, Oman, Bahrain, Qatar, Jordan, Syria, Lebanon, Algeria, Libya, Tunisia and Morocco.
In the US the FDA has cleared ActiPatch Therapy for post operative plastic surgery. The product is being distributed and evaluated for additional uses by established medical device and pharmaceutical companies. This is BioElectronics first international agreement for the $20 billion dollar worldwide soft tissue injury market. Management anticipates Canadian, European, and other international product distribution by the end of summer.
For more information visit http://www.bioelectronicscorp.com/.
CAUTIONARY STATEMENT FOR PURPOSES OF THE "SAFE HARBOR" PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Statements other than historical facts contained in this press release concerning our business strategy and plans of management for future operations are "forward-looking statements." Such statements are based on management's beliefs and assumptions and on information currently available and involve certain known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors include, among others, our ability to finance our operations and the ability to obtain such financing; the successful completion of any prior and future acquisitions; any uncertainties relating to the integration of acquired businesses and operations; any disputes with, and claims asserted by, our creditors and other third parties; uncertainties relating to business and economic conditions in markets in which we operate; uncertainties relating to customer plans and commitments; the timely development and market acceptance of our products and the highly competitive industry in which we operate.
Contact: Andrew J. Whelan 301-682-4795 or Whelan@bioelectronicscorp.com
BioElectronics Corporation
The Distribution Agreement with New Horizon Investment and Development, a 12-year-old leading Egyptian distributor of medical devices for Siemens, Select Surgical, and others covers Egypt, Saudi Arabia, Kuwait, Yemen, Oman, Bahrain, Qatar, Jordan, Syria, Lebanon, Algeria, Libya, Tunisia and Morocco.
In the US the FDA has cleared ActiPatch Therapy for post operative plastic surgery. The product is being distributed and evaluated for additional uses by established medical device and pharmaceutical companies. This is BioElectronics first international agreement for the $20 billion dollar worldwide soft tissue injury market. Management anticipates Canadian, European, and other international product distribution by the end of summer.
For more information visit http://www.bioelectronicscorp.com/.
CAUTIONARY STATEMENT FOR PURPOSES OF THE "SAFE HARBOR" PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Statements other than historical facts contained in this press release concerning our business strategy and plans of management for future operations are "forward-looking statements." Such statements are based on management's beliefs and assumptions and on information currently available and involve certain known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors include, among others, our ability to finance our operations and the ability to obtain such financing; the successful completion of any prior and future acquisitions; any uncertainties relating to the integration of acquired businesses and operations; any disputes with, and claims asserted by, our creditors and other third parties; uncertainties relating to business and economic conditions in markets in which we operate; uncertainties relating to customer plans and commitments; the timely development and market acceptance of our products and the highly competitive industry in which we operate.
Contact: Andrew J. Whelan 301-682-4795 or Whelan@bioelectronicscorp.com
BioElectronics Corporation
© 2004 PR Newswire
